IRIS Accounts Production v25.3.0.601 04535873 director 1.4.24 31.3.25 31.3.25 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh045358732024-03-31045358732025-03-31045358732024-04-012025-03-31045358732023-03-31045358732023-04-012024-03-31045358732024-03-3104535873ns15:EnglandWales2024-04-012025-03-3104535873ns14:PoundSterling2024-04-012025-03-3104535873ns10:Director12024-04-012025-03-3104535873ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3104535873ns10:SmallEntities2024-04-012025-03-3104535873ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3104535873ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3104535873ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3104535873ns10:FullAccounts2024-04-012025-03-310453587312024-04-012025-03-3104535873ns10:CompanySecretary12024-04-012025-03-3104535873ns10:RegisteredOffice2024-04-012025-03-3104535873ns5:CurrentFinancialInstruments2025-03-3104535873ns5:CurrentFinancialInstruments2024-03-3104535873ns5:ShareCapital2025-03-3104535873ns5:ShareCapital2024-03-3104535873ns5:RetainedEarningsAccumulatedLosses2025-03-3104535873ns5:RetainedEarningsAccumulatedLosses2024-03-3104535873ns5:NetGoodwill2024-04-012025-03-3104535873ns5:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3104535873ns5:FurnitureFittings2024-04-012025-03-3104535873ns5:NetGoodwill2024-03-3104535873ns5:NetGoodwill2025-03-3104535873ns5:NetGoodwill2024-03-3104535873ns5:ShortLeaseholdAssetsns5:LandBuildings2024-03-3104535873ns5:FurnitureFittings2024-03-3104535873ns5:ShortLeaseholdAssetsns5:LandBuildings2024-04-012025-03-3104535873ns5:ShortLeaseholdAssetsns5:LandBuildings2025-03-3104535873ns5:FurnitureFittings2025-03-3104535873ns5:ShortLeaseholdAssetsns5:LandBuildings2024-03-3104535873ns5:FurnitureFittings2024-03-3104535873ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3104535873ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-31
REGISTERED NUMBER: 04535873 (England and Wales)















GALLEYWOOD PHARMACY LIMITED

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025






GALLEYWOOD PHARMACY LIMITED (REGISTERED NUMBER: 04535873)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025










Page

Company Information 1

Balance Sheet 2 to 3

Notes to the Financial Statements 4 to 6


GALLEYWOOD PHARMACY LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2025







DIRECTOR: Mr Nikesh Patel





SECRETARY: Mrs Lalita Sharma Patel





REGISTERED OFFICE: 7 Jardine House
Harrovian Business Village
Bessborough Road
Harrow
Middlesex
HA1 3EX





REGISTERED NUMBER: 04535873 (England and Wales)





ACCOUNTANTS: TG Associates Limited
Chartered Accountants
7 Jardine House
Harrovian Business Village
Bessborough Road
Harrow
Middlesex
HA1 3EX

GALLEYWOOD PHARMACY LIMITED (REGISTERED NUMBER: 04535873)

BALANCE SHEET
31 MARCH 2025

31.3.25 31.3.24
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 49,183 61,479
49,183 61,479

CURRENT ASSETS
Stocks 39,400 39,400
Debtors 6 115,186 110,339
Cash at bank and in hand 69,039 175,595
223,625 325,334
CREDITORS
Amounts falling due within one year 7 190,353 315,709
NET CURRENT ASSETS 33,272 9,625
TOTAL ASSETS LESS CURRENT
LIABILITIES

82,455

71,104

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 82,355 71,004
82,455 71,104

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

GALLEYWOOD PHARMACY LIMITED (REGISTERED NUMBER: 04535873)

BALANCE SHEET - continued
31 MARCH 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 October 2025 and were signed by:





Mr Nikesh Patel - Director


GALLEYWOOD PHARMACY LIMITED (REGISTERED NUMBER: 04535873)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025


1. STATUTORY INFORMATION

Galleywood Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Fees receivable is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 18% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


GALLEYWOOD PHARMACY LIMITED (REGISTERED NUMBER: 04535873)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2024 - 7 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2024
and 31 March 2025 153,000
AMORTISATION
At 1 April 2024
and 31 March 2025 153,000
NET BOOK VALUE
At 31 March 2025 -
At 31 March 2024 -

GALLEYWOOD PHARMACY LIMITED (REGISTERED NUMBER: 04535873)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


5. TANGIBLE FIXED ASSETS
Fixtures
Short and
leasehold fittings Totals
£    £    £   
COST
At 1 April 2024
and 31 March 2025 5,972 146,060 152,032
DEPRECIATION
At 1 April 2024 4,472 86,081 90,553
Charge for year 300 11,996 12,296
At 31 March 2025 4,772 98,077 102,849
NET BOOK VALUE
At 31 March 2025 1,200 47,983 49,183
At 31 March 2024 1,500 59,979 61,479

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Trade debtors 97,284 96,171
Other debtors 17,902 14,168
115,186 110,339

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Trade creditors 126,840 149,955
Taxation and social security 18,184 38,762
Other creditors 45,329 126,992
190,353 315,709